I found this recent review on ivermectin data, which looks interesting and appears to have some very positive data behind it, albeit a lot of it is pre full publication.. However, I suspect that as it is a generic and not licensed or produced in some countries e.g. the UK for any indication that this may get overlooked as it will be of little interest to the mainstream Pharma sector.
See https://covid19criticalcare.com/wp-c...IN-Summary.pdf
There needs to be some high quality trials undertaken very rapidly to take a proper look at this compound, but I am not able to determine if there are any of a suitable design, size or quality underway. What do we think? We do still need compounds that will fill the gap around vaccines (limitations in production capacity and roll outs), especially if (as per gsgs' post above) we get a rapid vaccine escape.
See https://covid19criticalcare.com/wp-c...IN-Summary.pdf
There needs to be some high quality trials undertaken very rapidly to take a proper look at this compound, but I am not able to determine if there are any of a suitable design, size or quality underway. What do we think? We do still need compounds that will fill the gap around vaccines (limitations in production capacity and roll outs), especially if (as per gsgs' post above) we get a rapid vaccine escape.
Comment